Tonix Pharmaceuticals Launches National Awareness Campaign on the Impact of Gastroparesis or Stomach Paralysis on the Absorption of Oral Migraine…
Gastroparesis slows the ability of the stomach to empty into the small intestine and thereby can delay absorption of oral medications into the bloodstream
Nurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit
SAN FRANCISCO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix, will present an update on Nurix’s Degrader-Antibody Conjugate (DAC) platform at the ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit being held in Boston from September 9-10, 2024.
Go here to see the original:
Nurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit
Cartesian Therapeutics Announces New Employment Inducement Grant
GAITHERSBURG, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of an inducement award to a new employee. On September 3, 2024, the Company issued to this employee an option to purchase 3,864 shares of the Company’s common stock with an exercise price of $13.12, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The option was granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by the Company’s board of directors. The option vests as to 25% on September 3, 2025, and then in three equal annual installments thereafter such that the option will be fully vested on September 3, 2028. The option has a ten-year term. The option was granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employee’s entry into employment with the Company.
Continue reading here:
Cartesian Therapeutics Announces New Employment Inducement Grant
Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer…
NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced new clinical and preclinical data from studies evaluating naxitamab and GD2-SADA, respectively, in neuroblastoma. The results are summarized in poster presentations scheduled to be presented September 6 – 7, 2024, at the American Academy of Cancer Research (“AACR”) Special Conference in the Advances in Pediatric Cancer Research in Toronto, Canada.
Read the rest here:
Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer...
Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant
Clairvoyant currently executing a fully randomized multi-country Phase IIb clinical trial evaluating a synthetic psilocybin candidate as a potential therapeutic for Alcohol Use Disorder (AUD)
Continue reading here:
Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant
Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacyin Mental Health and Addiction Treatments
See the original post here:
Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacy in Mental Health and Addiction Treatments
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease
Results from this trial are expected in 2025 Results from this trial are expected in 2025
Go here to read the rest:
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease
Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences
SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is scheduled to present at various upcoming investor and scientific conferences.
Visit link:
Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences